Meetings: National Eye Institute

Federal Register: April 21, 2010 (Volume 75, Number 76)

Notices

Page 20853-20854

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

DOCID:fr21ap10-77

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections

Page 20854

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Eye Institute Special Emphasis

Panel, Immunosuppression for Eye Diseases.

Date: April 20, 2010.

Time: 3 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: National Eye Institute, 5635 Fishers Lane, 1300,

Bethesda, MD 20892.

Contact Person: Samuel Rawlings, PhD, Chief, Scientific Review

Branch, Division of Extramural Research, National Eye Institute, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892-9300, 301-451-2020, rawlings@nei.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93867, Vision

Research, National Institutes of Health, HHS)

Dated: April 8, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

FR Doc. 2010-8846 Filed 4-20-10; 8:45 am

BILLING CODE 4140-01-M

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT